Treatment of Hypertriglyceridemia

Treatment Algorithm Based on Triglyceride Severity

The treatment of hypertriglyceridemia is determined by the severity of triglyceride elevation, with lifestyle modifications forming the foundation for all patients, while pharmacologic therapy selection depends on whether the primary goal is preventing pancreatitis (triglycerides ≥500 mg/dL) or reducing cardiovascular risk (triglycerides <500 mg/dL). 1

Classification and Risk Stratification

Triglyceride levels are classified as: Normal (<150 mg/dL), Mild (150-199 mg/dL), Moderate (200-499 mg/dL), Severe (500-999 mg/dL), and Very Severe (≥1,000 mg/dL). 1, 2 Severe and very severe levels carry a 14% risk of acute pancreatitis, making immediate intervention mandatory. 1, 3

Lifestyle Modifications (All Patients)

Lifestyle changes are the cornerstone of treatment and must be implemented regardless of pharmacologic therapy. 1, 4

Weight Loss and Physical Activity

Target 5-10% body weight reduction, which produces a 20% decrease in triglycerides—the single most effective lifestyle intervention. 1, 3
In some patients, weight loss can reduce triglyceride levels by up to 50-70%. 1
Engage in ≥150 minutes/week of moderate-intensity aerobic activity (or 75 minutes/week vigorous activity), which reduces triglycerides by approximately 11%. 1, 3

Dietary Modifications by Severity

For mild to moderate hypertriglyceridemia (150-499 mg/dL): 1, 2

Restrict added sugars to <6% of total daily calories, as sugar intake directly increases hepatic triglyceride production. 1, 3
Limit total dietary fat to 30-35% of total calories. 1, 2
Restrict saturated fats to <7% of total energy intake, replacing with monounsaturated or polyunsaturated fats. 1, 3
Increase soluble fiber to >10 g/day from sources like oats, beans, and vegetables. 1
Consume ≥2 servings (8+ ounces) per week of fatty fish rich in omega-3 fatty acids (salmon, trout, sardines). 1, 3

For severe hypertriglyceridemia (500-999 mg/dL): 1, 2

Restrict total dietary fat to 20-25% of total daily calories. 1, 2
Eliminate all added sugars completely. 1, 2

For very severe hypertriglyceridemia (≥1,000 mg/dL): 1, 2

Implement extreme dietary fat restriction to 10-15% of total calories (or <5% until triglycerides fall below 1,000 mg/dL). 1, 2
Complete elimination of all added sugars. 1, 2

Alcohol Consumption

Limit or completely avoid alcohol consumption, as even 1 ounce daily increases triglycerides by 5-10%. 1, 3
Complete abstinence from alcohol is mandatory for patients with severe hypertriglyceridemia (≥500 mg/dL) to prevent hypertriglyceridemic pancreatitis. 1, 3

Pharmacologic Therapy Algorithm

Step 1: Evaluate and Address Secondary Causes First

Before initiating pharmacologic therapy, evaluate and treat secondary causes: 1, 4

Uncontrolled diabetes mellitus: Optimizing glycemic control can reduce triglycerides by 20-50% independent of lipid medications and is often the primary driver of severe hypertriglyceridemia. 1, 3
Hypothyroidism: Check TSH and treat before expecting full response to lipid-lowering therapy. 1, 3
Chronic kidney disease or nephrotic syndrome: Assess renal function (creatinine, eGFR). 1
Medications that raise triglycerides: Review thiazide diuretics, beta-blockers, estrogen therapy, corticosteroids, antiretrovirals, and antipsychotics—discontinue or substitute if possible. 1, 3

Step 2: Pharmacologic Therapy Based on Triglyceride Level

For Severe to Very Severe Hypertriglyceridemia (≥500 mg/dL)

Immediate pharmacologic intervention is mandatory to prevent acute pancreatitis, regardless of LDL-C levels or cardiovascular risk. 1, 2

Primary therapy: Fenofibrate 1, 2, 4

Initiate fenofibrate 54-160 mg daily immediately as first-line therapy before addressing LDL cholesterol. 1, 4
For patients with normal renal function (eGFR ≥60 mL/min/1.73 m²), start at 54 mg daily and titrate up to 160 mg daily based on response at 4-8 week intervals. 1, 4
For patients with mild to moderately impaired renal function (eGFR 30-59 mL/min/1.73 m²), initiate at 54 mg daily and do not exceed this dose. 1, 4
Fenofibrate is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²). 4
Fenofibrate provides 30-50% triglyceride reduction. 1, 3, 4
Take fenofibrate with meals to optimize bioavailability. 4

Monitoring for fenofibrate therapy: 1

Monitor renal function within 3 months after fenofibrate initiation and every 6 months thereafter. 1
Monitor liver function tests and creatine kinase at baseline and 3 months after initiation. 1
Reassess fasting lipid panel at 4-8 week intervals after initiating or adjusting fenofibrate. 1, 4

Once triglycerides fall below 500 mg/dL: 1

Reassess LDL-C and consider adding statin therapy if LDL-C is elevated or cardiovascular risk is high. 1
Target LDL-C <100 mg/dL (or <70 mg/dL for very high-risk patients). 1

For Moderate Hypertriglyceridemia (200-499 mg/dL)

Statins are first-line pharmacologic therapy when cardiovascular risk is elevated (10-year ASCVD risk ≥7.5%, established ASCVD, or diabetes). 1, 2, 3

Primary therapy: Statins 1, 2

Initiate moderate-to-high intensity statin therapy (atorvastatin 20-40 mg or rosuvastatin 10-20 mg daily). 1
Statins provide 10-30% dose-dependent triglyceride reduction plus proven cardiovascular benefit. 1, 3
Target LDL-C <100 mg/dL and non-HDL-C <130 mg/dL. 1

If triglycerides remain >200 mg/dL after 3 months of optimized lifestyle modifications and statin therapy: 1

Consider adding prescription omega-3 fatty acids (icosapent ethyl 2-4g daily) if patient has established cardiovascular disease OR diabetes with ≥2 additional cardiovascular risk factors. 1, 2
Alternatively, consider adding fenofibrate 54-160 mg daily if icosapent ethyl criteria are not met. 1

For Mild Hypertriglyceridemia (150-199 mg/dL)

For patients aged 40-75 years with 10-year ASCVD risk ≥7.5%: 1

Consider initiating moderate-intensity statin therapy, as persistently elevated triglycerides ≥175 mg/dL constitute a cardiovascular risk-enhancing factor. 1

For patients with 10-year ASCVD risk 5% to <7.5%: 1

Patient-clinician discussion regarding statin initiation is appropriate. 1

Prescription Omega-3 Fatty Acids (Icosapent Ethyl)

Icosapent ethyl (pure EPA) 2g twice daily is indicated as adjunct to maximally tolerated statin therapy for patients with triglycerides ≥150 mg/dL who have EITHER: 1, 2, 3

Established cardiovascular disease, OR
Diabetes with ≥2 additional cardiovascular risk factors

Evidence and efficacy: 1, 5

The REDUCE-IT trial demonstrated a 25% reduction in major adverse cardiovascular events (number needed to treat = 21). 1, 5
Icosapent ethyl is the only triglyceride-lowering therapy FDA-approved for cardiovascular risk reduction. 1
Provides 20-50% triglyceride reduction when used as adjunctive therapy. 1

Safety consideration: 1

Monitor for increased risk of atrial fibrillation (3.1% hospitalization rate versus 2.1% on placebo). 1

Important distinction: 1

Over-the-counter fish oil supplements are NOT equivalent to prescription formulations and should not be substituted. 1
Dietary omega-3 from fatty fish (≥2 servings/week) is recommended as part of lifestyle modification but does not replace prescription omega-3 for cardiovascular risk reduction. 1

Combination Therapy: Statin Plus Fibrate

When combining fenofibrate with statins (for patients with both elevated LDL-C and severe hypertriglyceridemia): 1, 3

Critical safety considerations: 1

Use fenofibrate, NOT gemfibrozil, when combining with statins. Fenofibrate has a significantly better safety profile because it does not inhibit statin glucuronidation, unlike gemfibrozil. 1
Use lower statin doses to minimize myopathy risk, particularly in patients >65 years or with renal disease. 1
Monitor creatine kinase levels and muscle symptoms at baseline and during therapy. 1
Take fenofibrate in the morning and statins in the evening to minimize peak dose concentrations. 1

Evidence limitations: 1

The ACCORD trial demonstrated no reduction in cardiovascular events with fenofibrate plus simvastatin compared to simvastatin alone in diabetic patients. 1
Combination therapy increases myopathy risk and should be reserved for cases where lifestyle modifications and monotherapy fail. 1

Treatment Goals and Monitoring

Treatment Goals by Severity

For severe to very severe hypertriglyceridemia (≥500 mg/dL): 1, 2

Primary goal: Rapid reduction of triglycerides to <500 mg/dL to eliminate pancreatitis risk. 1, 2
Secondary goal: Further reduction to <200 mg/dL (ideally <150 mg/dL) to reduce cardiovascular risk. 1

For moderate hypertriglyceridemia (200-499 mg/dL): 1

Primary goal: Triglycerides <200 mg/dL (ideally <150 mg/dL). 1
Secondary goal: Non-HDL-C <130 mg/dL (calculated as total cholesterol minus HDL-C). 1
LDL-C goal: <100 mg/dL for high-risk patients (or <70 mg/dL for very high-risk patients). 1

Monitoring Schedule

Reassess fasting lipid panel in 6-12 weeks after implementing lifestyle modifications. 1, 3
Reassess lipids 4-8 weeks after initiating or adjusting pharmacotherapy. 1, 3
Monitor liver function tests and creatine kinase if fibrates are added, particularly at baseline and 3 months after initiation. 1, 3
Monitor renal function within 3 months after fenofibrate initiation and every 6 months thereafter. 1
Once goals are achieved, follow-up every 6-12 months. 1

Critical Pitfalls to Avoid

Do not delay fibrate therapy while attempting lifestyle modifications alone in patients with triglycerides ≥500 mg/dL—pharmacologic therapy is mandatory. 1

Do not start with statin monotherapy when triglycerides are ≥500 mg/dL, as statins provide only 10-30% triglyceride reduction and are insufficient for preventing pancreatitis at this level. 1

Do not discontinue statins in favor of fibrate monotherapy for patients with cardiovascular risk or established disease, as statins provide proven mortality benefit through LDL-C reduction. 1

Do not use gemfibrozil when combining with statins—use fenofibrate instead due to significantly lower myopathy risk. 1

Do not overlook the importance of glycemic control in diabetic patients, as poor glucose control is often the primary driver of severe hypertriglyceridemia and optimizing it can be more effective than additional medications. 1, 3

Do not use over-the-counter fish oil supplements expecting cardiovascular benefit—only prescription icosapent ethyl has proven efficacy. 1

Therapy should be withdrawn in patients who do not have an adequate response after two months of treatment with the maximum recommended dose of fenofibrate 160 mg once daily. 4

What are the treatment options for a patient with hypertriglyceridemia?

Help us tailor your experience